Treatment for Warfarin-Induced Skin Necrosis

Immediate Management

The American College of Emergency Physicians recommends immediate discontinuation of warfarin, administration of vitamin K, replenishment of vitamin K-dependent factors, and switching to heparin for ongoing anticoagulation needs, along with appropriate wound management, when warfarin-induced skin necrosis is suspected 1, 2
Initiate heparin therapy for continued anticoagulation if needed for underlying thrombotic condition, as recommended by the American College of Emergency Physicians 1, 2
Replenish vitamin K-dependent factors through administration of fresh frozen plasma (FFP) or 4-factor prothrombin complex concentrates (PCC), as suggested by the American College of Chest Physicians 3

Assess the extent of skin necrosis, documenting affected areas on a body map, and provide appropriate wound care to prevent secondary infections, as recommended by Praxis Medical Insights 4
Perform surgical debridement of necrotic tissue as needed, as suggested by the American College of Emergency Physicians 1, 2
Consider skin grafting for extensive areas of necrosis, as recommended by the American College of Emergency Physicians 1, 2

Warfarin-induced skin necrosis occurs in 0.01% to 0.1% of patients who begin warfarin therapy, with symptoms typically beginning 3-8 days after initiation of therapy, as reported by the American College of Emergency Physicians 1, 2
The American College of Cardiology notes that the condition is caused by extensive thrombosis of venules and capillaries within subcutaneous fat, and that risk factors include protein C and S deficiencies 5, 3
Middle-aged, perimenopausal women with venous thromboembolism are at increased risk, as reported by the American College of Emergency Physicians 1, 2
Large loading doses of warfarin also increase the risk, as noted by the American College of Emergency Physicians 1, 2

For patients requiring continued anticoagulation, the American College of Emergency Physicians recommends heparin or low molecular weight heparin as the preferred alternative 1, 2
If warfarin must be restarted due to clinical necessity, the American College of Cardiology suggests beginning with a low dose (e.g., 2 mg daily) and administering concurrent therapeutic doses of heparin, with gradual increase of warfarin dose over several weeks 5, 6

Lesions typically appear on fatty areas, most commonly the breasts, followed by thighs and buttocks, as reported by the American College of Emergency Physicians 1, 2

Failing to consider protein C and S deficiencies in patients with warfarin-induced skin necrosis, as noted by Praxis Medical Insights, can lead to increased morbidity and mortality 4
Inadequate wound care leading to secondary infections, as reported by Praxis Medical Insights, can also increase morbidity and mortality 4
Restarting warfarin without appropriate precautions in patients who require continued anticoagulation, as warned by the American College of Cardiology, can also lead to adverse outcomes 5, 6

The pathophysiology of warfarin-induced skin necrosis involves extensive thrombosis of venules and capillaries within subcutaneous fat, with protein C depleting faster than factors II, IX, and X, creating a transient hypercoagulable state in the first 3-8 days of therapy, particularly in areas with high subcutaneous fat content 7
Protein C and S deficiency is strongly associated with warfarin-induced skin necrosis, though the condition also occurs in patients without these deficiencies 7
High-risk populations include patients with heparin-induced thrombocytopenia transitioning to warfarin, and those receiving large loading doses of warfarin 7

Typical presentation of warfarin-induced skin necrosis occurs 3-8 days after warfarin initiation, with initial symptoms including pain and erythema, often disproportionate to visible findings, and lesion characteristics progressing from petechial lesions to purpuric patches, hemorrhagic bullae, and eschar formation 7

For patients requiring lifelong anticoagulation after warfarin-induced skin necrosis, a gradual approach to restarting warfarin is recommended, beginning with a very low dose (2 mg daily) and providing concurrent therapeutic-dose parenteral anticoagulation (heparin or LMWH) as a "bridge", to avoid abrupt protein C depletion 7
Alternative anticoagulants to consider include low molecular weight heparin for long-term use, and direct oral anticoagulants (DOACs), though not specifically addressed in guidelines for this indication 8